<DOC>
	<DOC>NCT00603902</DOC>
	<brief_summary>The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.</brief_summary>
	<brief_title>BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management</brief_title>
	<detailed_description>Randomized, double-blind, placebo-controlled, parallel-group assessment of the effects of lorcaserin hydrochloride during 52 weeks of administration to overweight or obese male and female volunteers aged 18 to 65 years inclusive.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Overweight and/or obese men and women with a body mass index (BMI) 30 to 45 kg/m2 with or without a comorbid condition (e.g., hypertension, dyslipidemia, CV disease, glucose intolerance, sleep apnea), or 27 to 29.9 kg/m2 with at least one comorbid condition. Ability to complete a 1 year study Pregnancy Diabetes mellitus (type I, II or other) History of symptomatic heart valve disease Serious or unstable current or past medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOSSOM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>